Compare VBIX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VBIX | PMN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 23.5M |
| IPO Year | N/A | N/A |
| Metric | VBIX | PMN |
|---|---|---|
| Price | $1.46 | $8.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $72.67 |
| AVG Volume (30 Days) | 34.4K | ★ 41.4K |
| Earning Date | 08-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,056,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $6.27 |
| 52 Week High | $9.80 | $39.75 |
| Indicator | VBIX | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 30.17 | 93.27 |
| Support Level | $1.50 | $7.35 |
| Resistance Level | $1.91 | $7.95 |
| Average True Range (ATR) | 0.18 | 0.52 |
| MACD | 0.04 | 0.59 |
| Stochastic Oscillator | 6.27 | 100.00 |
ViewBix Inc operates in the field of digital advertising. Along with its subsidiaries, the company performs two main activities that are reported as separate operating segments: the search segment and the digital content segment. Maximum revenue is generated from the digital content segment, which is engaged in the creation and editing of content, in different languages, for different target audiences, to generate revenues from advertising platforms, including Google, Facebook, Yahoo, and Apple, by utilizing such content to obtain internet user traffic for its customers. The search segment develops various technological software solutions, which perform automation, optimization, and monetization of internet campaigns, to obtain and route internet user traffic to its customers.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.